IL311963A - Antibodies and methods of using them - Google Patents
Antibodies and methods of using themInfo
- Publication number
- IL311963A IL311963A IL311963A IL31196324A IL311963A IL 311963 A IL311963 A IL 311963A IL 311963 A IL311963 A IL 311963A IL 31196324 A IL31196324 A IL 31196324A IL 311963 A IL311963 A IL 311963A
- Authority
- IL
- Israel
- Prior art keywords
- antibody
- amino acid
- seq
- acid sequence
- cdr1
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2458/00—Labels used in chemical analysis of biological material
- G01N2458/15—Non-radioactive isotope labels, e.g. for detection by mass spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2878—Muscular dystrophy
- G01N2800/2885—Duchenne dystrophy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Genetics & Genomics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163256511P | 2021-10-15 | 2021-10-15 | |
| PCT/US2022/078180 WO2023064947A1 (en) | 2021-10-15 | 2022-10-15 | Antibodies and methods of using thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL311963A true IL311963A (en) | 2024-06-01 |
Family
ID=84331799
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL311963A IL311963A (en) | 2021-10-15 | 2022-10-15 | Antibodies and methods of using them |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240425572A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4415822A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024542939A (cg-RX-API-DMAC7.html) |
| CA (1) | CA3234162A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL311963A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023064947A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026006341A1 (en) | 2024-06-24 | 2026-01-02 | Regenxbio Inc. | Microdystrophin gene therapy administration for treatment of dystrophinopathies |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4588585A (en) | 1982-10-19 | 1986-05-13 | Cetus Corporation | Human recombinant cysteine depleted interferon-β muteins |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US5681718A (en) | 1986-03-14 | 1997-10-28 | Celltech Limited | Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| MX9204374A (es) | 1991-07-25 | 1993-03-01 | Idec Pharma Corp | Anticuerpo recombinante y metodo para su produccion. |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| US6174666B1 (en) | 1992-03-27 | 2001-01-16 | The United States Of America As Represented By The Department Of Health And Human Services | Method of eliminating inhibitory/instability regions from mRNA |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| JP2003531588A (ja) | 2000-04-11 | 2003-10-28 | ジェネンテック・インコーポレーテッド | 多価抗体とその用途 |
| GB0216648D0 (en) | 2002-07-18 | 2002-08-28 | Lonza Biologics Plc | Method of expressing recombinant protein in CHO cells |
| US20080187954A1 (en) | 2004-03-10 | 2008-08-07 | Lonza Ltd. | Method For Producing Antibodies |
| CA2581208A1 (en) | 2004-08-30 | 2006-03-09 | Lonza Biologics Plc. | Affinity- plus ion exchange- chromatography for purifying antibodies |
| US7691980B2 (en) | 2007-01-09 | 2010-04-06 | Bio-Rad Laboratories, Inc. | Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers |
| JP6157046B2 (ja) | 2008-01-07 | 2017-07-05 | アムジェン インコーポレイテッド | 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法 |
| EP2238154B1 (en) | 2008-01-18 | 2015-09-16 | Bio-Rad Laboratories, Inc. | Enhanced purification of phosphorylated and non-phosphorylated biomolecules by apatite chromatography |
| US10093733B2 (en) | 2014-12-11 | 2018-10-09 | Abbvie Inc. | LRP-8 binding dual variable domain immunoglobulin proteins |
| TWI908746B (zh) | 2019-11-28 | 2025-12-21 | 美商銳進科斯生物股份有限公司 | 微小肌縮蛋白基因療法之構築體及其用途 |
| US20240003898A1 (en) * | 2020-10-30 | 2024-01-04 | Pfizer Inc. | Methods for measuring dystrophin in tissue samples |
-
2022
- 2022-10-15 US US18/701,201 patent/US20240425572A1/en active Pending
- 2022-10-15 JP JP2024522269A patent/JP2024542939A/ja active Pending
- 2022-10-15 CA CA3234162A patent/CA3234162A1/en active Pending
- 2022-10-15 WO PCT/US2022/078180 patent/WO2023064947A1/en not_active Ceased
- 2022-10-15 EP EP22802457.6A patent/EP4415822A1/en active Pending
- 2022-10-15 IL IL311963A patent/IL311963A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20240425572A1 (en) | 2024-12-26 |
| JP2024542939A (ja) | 2024-11-19 |
| EP4415822A1 (en) | 2024-08-21 |
| CA3234162A1 (en) | 2023-04-20 |
| WO2023064947A1 (en) | 2023-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gaciarz et al. | Systematic screening of soluble expression of antibody fragments in the cytoplasm of E. coli | |
| JP3105898B2 (ja) | 組換えｄｎａタンパクの製造方法 | |
| US20230228772A1 (en) | Methods For Detecting Phosphorylated Alpha-Synuclein | |
| JP7692404B2 (ja) | 多重特異性抗原結合分子を含む組成物における不純物分子の分析方法 | |
| CN117866087B (zh) | 一种抗pTau181单克隆抗体及其应用 | |
| JP7307158B2 (ja) | 抗ヒト心筋型トロポニンｉ抗体及びその応用 | |
| US20210047431A1 (en) | Anti-pla2-gib antibodies and the uses thereof | |
| IL311963A (en) | Antibodies and methods of using them | |
| Killer et al. | Cryo-EM structure of an atypical proton-coupled peptide transporter: di-and tripeptide permease C | |
| KR102785236B1 (ko) | 항 인간 심근 트로포닌 i의 항체 및 그 사용 | |
| Mishra et al. | Development of monoclonal antibodies to detect for SARS-CoV-2 proteins | |
| JP7365050B2 (ja) | 融合タンパク質、及びそれを用いた高密度リポタンパク質の測定キット | |
| JP2019522800A (ja) | 総及びＳ１２９リン酸化α−シヌクレインの検出アッセイ | |
| CN101463084B (zh) | 与A-beta寡聚体特异性结合的基因工程单克隆抗体 | |
| JP2023182682A (ja) | 細胞外小胞の膜結合タンパク質を検出及び定量化するための方法 | |
| KR20160023725A (ko) | 시스테인으로 변형된 닭의 항체 및 이를 이용한 부위-특이적 접합 | |
| US20160237144A1 (en) | Thermus thermophilus slyd fkbp domain specific antibodies | |
| US20250296994A1 (en) | Monoclonal antibody, reagent for measuring crtac1b, reagent kit, and method for measuring crtac1b | |
| Girard | Investigating the Determinants of Antibody Binding Against a Cancer-Related Glycoprotein The Crucial Role of the Heavy Chain CDRs | |
| Thongkum et al. | Comparative evaluation of E. coli expression systems for soluble hScFv-IL-17A with an unpaired CDR-L3 cysteine | |
| KR20240113649A (ko) | 항-베타 아밀로이드 항체 및 이의 용도 | |
| CN112979799B (zh) | 一种包含血红蛋白抗原结构域的结合蛋白 | |
| WO2024229245A2 (en) | High throughput fab antibody fragment generation and ranking | |
| Hwang et al. | Cryo-EM structures of an anti-MLC1 Fab in apo and peptide-bound states reveal the structural basis of antigen recognition | |
| WO2025162587A1 (en) | High affinity antibodies specifically binding to pepsinogen a |